{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.1","upperLimit":"13.5","value":"7.7"},{"comment":"Insufficient DoR events to estimate upper confidence limit.","groupId":"OG001","lowerLimit":"6.0","upperLimit":"NA","value":"13.1"},{"groupId":"OG002","lowerLimit":"8.1","upperLimit":"29.9","value":"21.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"125"},{"groupId":"OG002","value":"117"}],"units":"Participants"}],"description":"To determine the efficacy of durvalumab in combination with platinum-based chemotherapy (paclitaxel and carboplatin) followed by maintenance durvalumab or durvalumab with olaparib when compared to platinum-based chemotherapy in newly diagnosed advanced or recurrent endometrial cancer patients by assessment of DoR","dispersionType":"Inter-Quartile Range","groups":[{"description":"Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with durvalumab placebo (IV) Q3W.\n\nFollowing completion of chemotherapy treatment, participants without objective disease progression received durvalumab placebo (IV) Q4W and olaparib placebo (tablets) twice bd orally as maintenance treatment until disease progression.","id":"OG000","title":"Global Cohort - SoC"},{"description":"Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W.\n\nFollowing completion of chemotherapy treatment, participants without objective disease progression received 1500 mg durvalumab (IV) Q4W with olaparib placebo (tablets) bd orally as maintenance treatment until disease progression.","id":"OG001","title":"Global Cohort - SoC + Durvalumab"},{"description":"Platinum-based chemotherapy (paclitaxel and carboplatin) Q3W for a maximum of 6 cycles with 1120 mg durvalumab (IV) Q3W.\n\nFollowing completion of chemotherapy treatment, patients without objective disease progression received 1500 mg durvalumab (IV) Q4W with 300 mg olaparib (tablets) bd orally as maintenance treatment until disease progression.","id":"OG002","title":"Global Cohort - SoC + Durvalumab + Olaparib"}],"paramType":"MEDIAN","populationDescription":"All participants with confirmed response were included in the analysis. FAS consisting of all patients randomised as part of global enrolment including patients from China who were randomised before the global recruitment was closed (up to and including 20 Apr 2022). This endpoint was not assessed in the China cohort as it was not prespecified in the statistical analysis plan (SAP).","reportingStatus":"POSTED","timeFrame":"At baseline, every 9 wks up to 18 wks, then every 12 wks until objective radiological disease progression. Assessed until 12 Apr 2023 DCO, up to 35 months","title":"Duration of Response (DoR) Based on Investigator Assessment","type":"SECONDARY","unitOfMeasure":"Months"}